Intranasal Vaccination with Mycobacterium tuberculosis Vaccine Candidates
Author Information
Author(s): Sable Suraj B., Cheruvu Mani, Nandakumar Subhadra, Sharma Sunita, Bandyopadhyay Kakali, Kellar Kathryn L., Posey James E., Plikaytis Bonnie B., Amara Rama Rao, Shinnick Thomas M.
Primary Institution: Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
Hypothesis
Can intranasal vaccination induce a stronger immune response against Mycobacterium tuberculosis compared to subcutaneous vaccination?
Conclusion
Intranasal vaccination with the Apa-based vaccine candidates showed significant protection against tuberculosis in mice.
Supporting Evidence
- Intranasal BCG vaccination induced stronger T-cell responses in the lungs compared to subcutaneous vaccination.
- Nine recombinant proteins were evaluated for their immunogenicity following intranasal vaccination.
- Apa protein induced significant protection in the lungs and spleen against M. tuberculosis challenge.
- Both vaccination routes provided comparable levels of protection against tuberculosis.
Takeaway
This study found that giving a tuberculosis vaccine through the nose can help the body fight the disease better than giving it through a shot.
Methodology
The study compared immune responses in mice vaccinated intranasally versus subcutaneously with BCG and nine recombinant proteins.
Limitations
The study was conducted in mice, which may not fully represent human responses.
Participant Demographics
Female BALB/c mice, 6-8 weeks old.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website